Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship

Abstract

Worldwide, the leading cause of chronic liver disease is represented by nonalcoholic fatty liver disease (NAFLD) which has now become a global epidemic of the 21st century, affecting 1 in 4 adults, and which appears to be associated with the steadily increasing rates of metabolic syndrome and its components (obesity, type 2 diabetes mellitus (T2DM), and dyslipidemia). NAFLD has been reported to be associated with extrahepatic manifestations such as cardiovascular disease, T2DM, chronic kidney disease, extrahepatic malignancies (e.g., colorectal cancer), endocrine diseases (e.g., hypothyroidism, polycystic ovarian syndrome, psoriasis, and osteoporosis), obstructive sleep apnea, and iron overload. The prevalence of NAFLD is very high, affecting 25–30% of the world population and encloses two steps: (1) nonalcoholic fatty liver (NAFL), which includes steatosis only, and (2) nonalcoholic steatohepatitis (NASH) defined by the presence of steatosis and inflammation with hepatocyte ballooning, with or without fibrosis which can progress to liver fibrosis, hepatocellular carcinoma, and liver transplantation. Current data define a more complex relationship between NAFLD and T2DM than was previously believed, underlining a bidirectional and mutual association between the two entities. This review aims to summarize the current literature regarding the incidence of T2DM among patients with NAFLD and also the prevalence of NAFLD in T2DM patients, highlighting the recent key studies. Clinicians should screen, diagnose, and treat T2DM in patients with NAFLD in order to avoid short- and long-term complications.

1. Introduction

The incidence rate of chronic liver diseases increased through the years with a worrying rise of liver-related morbidity and mortality rates worldwide [1]. One of the major causes of chronic liver diseases is represented by nonalcoholic fatty liver disease (NAFLD) which has now become a global epidemic affecting 1 in 4 adults, with an estimated prevalence between 25% and 30%, and appears to be associated with the steadily increasing rates of metabolic syndrome (MetS) and its components (obesity, type 2 diabetes mellitus (T2DM), and dyslipidemia) [1–3]. The mandatory feature of NAFLD is the presence of liver steatosis (LS) in the absence of other causes of chronic liver disease [4]. Although initially NAFLD was considered as the hepatic manifestation of MetS, there is now clear evidence that NAFLD is a key driver in MetS and hepatic involvement is only one component of systemic multiorgan involvement [5, 6]. NAFLD encloses two distinct conditions with different histologic features and prognosis: (1) nonalcoholic fatty liver (NAFL), which includes steatosis only, and (2) nonalcoholic steatohepatitis (NASH) characterized by steatosis and inflammation with hepatocyte ballooning, with or without fibrosis, which can progress to liver fibrosis (LF), cirrhosis, hepatocellular carcinoma (HCC), and liver transplantation [7]. The prevalence of NASH among NAFLD patients ranges from 10% to 59% in patients who underwent liver biopsy [1], meaning that millions and millions of people worldwide are at risk of cirrhosis and its complications. Even more alarming is that the continuously increasing rates of MetS and its components parallel the rising prevalence of NASH, with obesity, T2DM, and MetS being the most important risk factors [8, 9].

Growing evidence clearly shows that NAFLD is a multiorgan disease, supporting a strong link between NAFLD and cardiovascular diseases (CVDs), T2DM, chronic kidney disease (CKD), extrahepatic malignancies (eg., colorectal cancer), obstructive sleep apnea (OSA), and various endocrinopathies (e.g., thyroid dysfunction, polycystic ovarian syndrome (PCOS), osteoporosis, psoriasis, hypothyroidism, and iron overload) [10, 11]. Although the primary site of NAFLD is the liver, the most common causes of mortality are CVDs, followed by extrahepatic malignancies such as colorectal cancer and then liver-related complications (cirrhosis and HCC) [5, 6, 12]. Considering the high clinical and economic burden of NAFLD, the main point in the management of these patients is an early acknowledgement of both hepatic and extrahepatic manifestations and their subsequent complications [11, 13, 14]. Current data outline a more complex relationship between NAFLD and T2DM than was previously thought, pointing out a bidirectional and mutual association between the two entities. Thus, clinicians should screen, diagnose, and treat T2DM in patients with NAFLD in order to avoid short- and long-term complications. Herein, this review aims to summarize the current literature regarding the incidence of T2DM among patients with NAFLD and also the prevalence of NAFLD in T2DM patients, highlighting recent key studies.

2. Relation between NAFLD and T2DM

Current data reveal a more complex relationship between NAFLD and T2DM than was previously believed, highlighting a bidirectional and mutual association between the two entities [11, 15, 16]. Considering that NAFLD and T2DM have similar physiopathological pathways, one can precede and/or promote the other [10, 17].

2.1. T2DM in Patients with NAFLD

NAFLD is associated with lipotoxicity which is secondary to the accumulation of triglyceride-derived toxic metabolites in the liver, pancreas, and muscles, which leads to the activation of the inflammation cascade and insulin resistance [18, 19]. The hepatic insulin resistance associated with NAFLD is the key driver for the development of T2DM among these patients.

The prevalence of T2DM in patients with NAFLD depends on the severity of NAFLD starting from 9.8% in mild NAFLD to 17.8% in moderate to severe NAFLD [20–22]. Although NAFLD is considered an independent risk factor for developing T2DM, with a 2-fold incidence increase in these individuals, patients with NASH have an up to threefold higher risk of developing incident T2DM compared with those with simple steatosis [20, 23, 24].

Despite evidence from several studies which demonstrated that high levels of NAFLD’s surrogate markers—gamma-glutamyl transferase and alanine aminotransferase (ALT)—were associated with a high incidence of T2DM, the predictive value of these biologic parameters is limited due to the possibility of normal levels among these patients [25–29]. As for ultrasonography-defined NAFLD (liver steatosis ≥20%) [30, 31], recent data showed a twofold to fivefold increased risk of T2DM [32].

Many large-population-based retrospective studies with a follow-up period of 3 to 6.2 years showed an increased incidence risk of T2DM among patients diagnosed with NAFLD (Table 1) [33–37, 42, 43]. Shibata et al. achieved a 4-year follow-up in 3189 patients among whom 1138 had NAFLD at baseline and reported an incidence of 1.8% vs. 8.1% in the non-NAFLD patients compared with those with NAFLD [33]. Similarly, 4 other retrospective studies which included Asian cohorts without T2DM, demonstrated that NAFLD was significantly associated with a high incidence of T2DM during follow-up [34–37]. In a similar manner, prospective studies which evaluated the prevalence of T2DM among patients with NAFLD have also reported an increased risk associated with baseline NAFLD [38–41]. Results from an Israeli cohort of 141 nondiabetic participants among which 24.8% had NAFLD, followed up for an average period of 6.08 ± 0.7 years, demonstrated a higher incidence of prediabetes and/or T2DM in patients with NAFLD than in subjects without NAFLD (74.3% vs. 48.1%) [39]. In a recent retrospective study conducted by Liu et al. which included 18,507 nondiabetic subjects, the prevalence of NAFLD was 18.77% with a 5-year T2DM incidence of 2.44%. The authors concluded that patients with baseline NAFLD had a higher risk incidence of T2DM, with an adjusted relative risk of 1.672 [43].

2.2. NAFLD in Patients with T2DM

Once established, T2DM may promote the progression to NASH and become an independent risk factor for chronic liver disease, including cirrhosis and HCC [10]. It has been reported that the presence of NAFLD among patients with T2DM determined a 2.2-fold risk increase in all-cause mortality, compared with those without NAFLD [15]. The estimated prevalence of NAFLD among patients with T2DM is about 75%, which is more than the prevalence in the general population [1].

Evidences from several recent cohort studies highlighted an increased incidence of NAFLD among patients diagnosed with T2DM, with an estimated prevalence ranging between 41.6% and 86% (Table 2) [8, 44–49]. For instance, Sporea et al. conducted a prospective study in which 534 patients diagnosed with T2DM were included. Patients with other causes of steatosis were excluded, and LF and steatosis were quantitatively assessed using vibration controlled transient elastography and the controlled attenuation parameter. The authors found an estimated prevalence of NAFLD of 76.1%. Moreover, severe steatosis was detected in 60.3%, while advanced LF had a prevalence of almost 20% [50]. Two other retrospective studies reported a similar prevalence of NAFLD among T2DM patients [45, 46].

3. Management of Patients with NAFLD and T2DM

The reciprocal relationship between T2DM and NAFLD leads to the progression of LF and is secondary to the development of liver-related complications with high morbidity and mortality rates. In order to avoid systemic multicollateral damage, it seems appropriate to screen patients with NAFLD for T2DM, and vice-versa. According to current European Guidelines, screening of T2DM in patients with NAFLD is mandatory, and it consists of random blood glucose or hemoglobin A1C [51]. Furthermore, screening for NAFLD and LF is recommended by the American Diabetes Association in patients diagnosed with T2DM which have elevated liver enzymes (ALT) or LS, while the American Association Society of Liver Disease is not in favour of routine screening in these patients [52, 53].

4. Conclusion

In light of current evidence, the clinical burden of NAFLD is not limited to liver-related complications, but is in fact, related to its extrahepatic manifestations such as CVD, T2DM, CKD, extrahepatic malignancies, OSA, and various endocrinopathies, with increased mortality rates. Our review highlights that the components of NAFLD (NASH and NAFL) lead to insulin resistance and T2DM through various physiopathological pathways, but also T2DM may promote the progression to NASH as an independent risk factor. Thus, clinicians should be aware of these NAFLD-related extrahepatic manifestations considering that an early acknowledgement of T2DM is the key point in the management of these patients.

Conflicts of Interest

The authors declare no conflicts of interest in this work.

Authors’ Contributions

All authors made substantial contributions to acquisition of data, or analysis, conception and design, and interpretation of data; took part in drafting of the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. All authors have read and agreed to the published version of the manuscript.

References

1. Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, and M. Wymer, “Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes,” Hepatology, vol. 64, no. 1, pp. 73–84, 2016. View at: Publisher Site | Google Scholar
2. C. D. Williams, J. Stengel, M. I. Asike et al., “Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study,” Gastroenterology, vol. 140, no. 1, pp. 124–131, 2011. View at: Publisher Site | Google Scholar
3. D. Kim, A. Touros, and W. R. Kim, “Nonalcoholic fatty liver disease and metabolic syndrome,” Clinics in Liver Disease, vol. 22, no. 1, pp. 133–140, 2018. View at: Publisher Site | Google Scholar
4. A. A. Li, A. Ahmed, and D. Kim, “Extrahepatic manifestations of nonalcoholic fatty liver disease,” Gut and Liver, vol. 14, no. 2, pp. 168–178, 2020. View at: Publisher Site | Google Scholar
5. L. A. Adams, J. F. Lymp, J. St. Sauver et al., “The natural history of nonalcoholic fatty liver disease: a population-based cohort study,” Gastroenterology, vol. 129, no. 1, pp. 113–121, 2005. View at: Publisher Site | Google Scholar
6. D. Kim, W. R. Kim, H. J. Kim, and T. M. Therneau, “Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States,” Hepatology, vol. 57, no. 4, pp. 1357–1365, 2013. View at: Publisher Site | Google Scholar
7. S. Singh, A. M. Allen, Z. Wang, L. J. Prokop, M. H. Murad, and R. Loomba, “Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies,” Clinical Gastroenterology and Hepatology, vol. 13, no. 4, pp. 643–654, 2015. View at: Publisher Site | Google Scholar
8. R. M. Williamson, J. F. Price, S. Glancy et al., “Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the edinburgh type 2 diabetes study,” Diabetes Care, vol. 34, no. 5, pp. 1139–1144, 2011. View at: Publisher Site | Google Scholar
9. Collaboration NCDRF, “Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults,” Lancet, vol. 390, pp. 2627–2642, 2017. View at: Google Scholar
10. Q. M. Anstee, G. Targher, and C. P. Day, “Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis,” Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 6, pp. 330–344, 2013. View at: Publisher Site | Google Scholar
11. C. D. Byrne and G. Targher, “NAFLD: a multisystem disease,” Journal of Hepatology, vol. 62, no. 1, pp. S47–S64, 2015. View at: Publisher Site | Google Scholar
12. J. P. Ong, A. Pitts, and Z. M. Younossi, “Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease,” Journal of Hepatology, vol. 49, no. 4, pp. 608–612, 2008. View at: Publisher Site | Google Scholar
13. C. Estes, H. Razavi, R. Loomba, Z. Younossi, and A. J. Sanyal, “Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease,” Hepatology, vol. 67, no. 1, pp. 123–133, 2018. View at: Publisher Site | Google Scholar
14. J. Wattacheril, “Extrahepatic manifestations of nonalcoholic fatty liver disease,” Gastroenterology Clinics of North America, vol. 49, no. 1, pp. 141–149, 2020. View at: Publisher Site | Google Scholar
15. L. A. Adams, Q. M. Anstee, H. Tilg, and G. Targher, “Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases,” Gut, vol. 66, no. 6, pp. 1138–1153, 2017. View at: Publisher Site | Google Scholar
16. G. Targher, G. Marchesini, and C. D. Byrne, “Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: causal association or epiphenomenon?” Diabetes & Metabolism, vol. 42, no. 3, pp. 142–156, 2016. View at: Publisher Site | Google Scholar
17. F. Bril and K. Cusi, “Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action,” Diabetes Care, vol. 40, no. 3, pp. 419–430, 2017. View at: Publisher Site | Google Scholar
18. K. Cusi, “Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications,” Gastroenterology, vol. 142, no. 4, pp. 711–725, 2012. View at: Publisher Site | Google Scholar
19. R. Lomonaco, C. Ortiz-Lopez, B. Orsak et al., “Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease,” Hepatology, vol. 55, no. 5, pp. 1389–1397, 2012. View at: Publisher Site | Google Scholar
20. M. Ekstedt, L. E. Franzén, U. L. Mathiesen et al., “Long-term follow-up of patients with NAFLD and elevated liver enzymes,” Hepatology, vol. 44, no. 4, pp. 865–873, 2006. View at: Publisher Site | Google Scholar
21. R. Loomba, M. Abraham, A. Unalp et al., “Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis,” Hepatology, vol. 56, no. 3, pp. 943–951, 2012. View at: Publisher Site | Google Scholar
22. A. Mantovani, C. D. Byrne, E. Bonora, and G. Targher, “Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis,” Diabetes Care, vol. 41, no. 2, pp. 372–382, 2018. View at: Publisher Site | Google Scholar
23. R. Zheng, Z. Du, M. Wang et al., “A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease,” Lipids Health Diseases, vol. 20, no. 1, p. 262, 2018. View at: Google Scholar
24. S. Ballestri, S. Zona, G. Targher et al., “Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis,” Journal of Gastroenterology and Hepatology, vol. 31, no. 5, pp. 936–944, 2016. View at: Publisher Site | Google Scholar
25. D.-H. Lee, M.-H. Ha, J.-H. Kim et al., “Gamma-glutamyltransferase and diabetes-a 4 year follow-up study,” Diabetologia, vol. 46, no. 3, pp. 359–364, 2003. View at: Publisher Site | Google Scholar
26. A. J. G. Hanley, K. Williams, A. Festa, L. E. Wagenknecht, R. B. D’Agostino, and S. M. Haffner, “Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study,” Diabetes, vol. 54, no. 11, pp. 3140–3147, 2005. View at: Publisher Site | Google Scholar
27. W. Goessling, J. M. Massaro, R. S. Vasan, R. B. D’Agostino, R. C. Ellison, and C. S. Fox, “Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease,” Gastroenterology, vol. 135, no. 6, pp. 1935–1944, 2008. View at: Publisher Site | Google Scholar
28. A. Fraser, R. Harris, N. Sattar, S. Ebrahim, G. Davey Smith, and D. A. Lawlor, “Alanine aminotransferase, -glutamyltransferase, and incident diabetes: the British women’s heart and health study and meta-analysis,” Diabetes Care, vol. 32, no. 4, pp. 741–750, 2009. View at: Publisher Site | Google Scholar
29. A. L. Fracanzani, L. Valenti, E. Bugianesi et al., “Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes,” Hepatology, vol. 48, no. 3, pp. 792–798, 2008. View at: Publisher Site | Google Scholar
30. S. Ballestri, F. Nascimbeni, E. Baldelli et al., “Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases,” Metabolism, vol. 72, pp. 57–65, 2017. View at: Publisher Site | Google Scholar
31. Q. Li, M. Dhyani, J. R. Grajo, C. Sirlin, and A. E. Samir, “Current status of imaging in nonalcoholic fatty liver disease,” World Journal of Hepatology, vol. 10, no. 8, pp. 530–542, 2018. View at: Publisher Site | Google Scholar
32. M. J. Armstrong, L. A. Adams, A. Canbay, and W.-K. Syn, “Extrahepatic complications of nonalcoholic fatty liver disease,” Hepatology, vol. 59, no. 3, pp. 1174–1197, 2014. View at: Publisher Site | Google Scholar
33. M. Shibata, Y. Kihara, M. Taguchi, M. Tashiro, and M. Otsuki, “Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men,” Diabetes Care, vol. 30, no. 11, pp. 2940–2944, 2007. View at: Publisher Site | Google Scholar
34. C.-H. Kim, J.-Y. Park, K.-U. Lee, J.-H. Kim, and H.-K. Kim, “Fatty liver is an independent risk factor for the development of type 2 diabetes in Korean adults,” Diabetic Medicine, vol. 25, no. 4, pp. 476–481, 2008. View at: Publisher Site | Google Scholar
35. J. C. Bae, E. J. Rhee, W. Y. Lee et al., “Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study,” Diabetes Care, vol. 34, no. 3, pp. 727–729, 2011. View at: Publisher Site | Google Scholar
36. K.-C. Sung, W.-S. Jeong, S. H. Wild, and C. D. Byrne, “Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes,” Diabetes Care, vol. 35, no. 4, pp. 717–722, 2012. View at: Publisher Site | Google Scholar
37. A. Kasturiratne, S. Weerasinghe, A. S. Dassanayake et al., “Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus,” Journal of Gastroenterology and Hepatology, vol. 28, no. 1, pp. 142–147, 2013. View at: Publisher Site | Google Scholar
38. S. K. Park, M. H. Seo, H. C. Shin, and J.-H. Ryoo, “Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study,” Hepatology, vol. 57, no. 4, pp. 1378–1383, 2013. View at: Publisher Site | Google Scholar
39. S. Zelber-Sagi, D. Shoham, I. Zvibel, S. Abu-Abeid, O. Shibolet, and S. Fishman, “Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients,” World Journal of Hepatology, vol. 9, no. 2, pp. 91–98, 2017. View at: Publisher Site | Google Scholar
40. G. Y. Chen, H. X. Cao, F. Li et al., “New risk-scoring system including non-alcoholic fatty liver disease for predicting incident type 2 diabetes in East China: shanghai Baosteel Cohort,” Journal of Diabetes Investigation, vol. 7, no. 2, pp. 206–211, 2016. View at: Publisher Site | Google Scholar
41. Y. Li, J. Wang, and Y. Tang, “Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: evidence from the Dongfeng-Tongji cohort study,” PLoS One, vol. 12, Article ID e0174291, 2017. View at: Publisher Site | Google Scholar
42. J. Ma, S.-J. Hwang, A. Pedley et al., “Bi-directional analysis between fatty liver and cardiovascular disease risk factors,” Journal of Hepatology, vol. 66, no. 2, pp. 390–397, 2017. View at: Publisher Site | Google Scholar
43. M. Liu, J. Wang, J. Zeng, X. Cao, and Y. He, “Association of NAFLD with diabetes and the impact of BMI changes: a 5-year cohort study based on 18,507 elderly,” The Journal of Clinical Endocrinology & Metabolism, vol. 102, no. 4, pp. 1309–1316, 2017. View at: Publisher Site | Google Scholar
44. W.-S. Lv, R.-X. Sun, and Y.-Y. Gao, “Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes,” World Journal of Gastroenterology, vol. 19, no. 20, pp. 3134–3142, 2013. View at: Publisher Site | Google Scholar
45. C. A. Silaghi, H. Silaghi, A. E. Craciun et al., “Age, abdominal obesity, and glycated hemoglobin are associated with carotid atherosclerosis in type 2 diabetes patients with nonalcoholic fatty liver disease,” Medical Ultrasonography, vol. 17, no. 3, pp. 300–307, 2015. View at: Publisher Site | Google Scholar
46. A. Mantovani, A. Rigamonti, S. Bonapace et al., “Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring,” Diabetes Care, vol. 39, no. 8, pp. 1416–1423, 2016. View at: Publisher Site | Google Scholar
47. K. Guo, L. Zhang, J. Lu et al., “Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes,” Journal of Diabetes and Its Complications, vol. 31, no. 1, pp. 80–85, 2017. View at: Publisher Site | Google Scholar
48. M. Yi, R.-P. Chen, R. Yang, and H. Chen, “Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with type 2 diabetes in South China,” Diabetic Medicine, vol. 34, no. 4, pp. 505–513, 2017. View at: Publisher Site | Google Scholar
49. X. Ding, Y. Xu, and Y. Wang, “Nonalcoholic fatty liver disease and associated metabolic risks of hypertension in type 2 diabetes: a crosssectional community-based study,” International Journal of Endocrinology, vol. 2017, Article ID 526256, 2017. View at: Publisher Site | Google Scholar
50. I. Sporea, R. Mare, A. Popescu et al., “Screening for liver fibrosis and steatosis in a large cohort of patients with type 2 diabetes using vibration controlled transient elastography and controlled attenuation parameter in a single-center real-life experience,” Journal of Clinical Medicine, vol. 9, no. 4, p. 1032, 2020. View at: Publisher Site | Google Scholar
51. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO), “EASL-EASD-EASO clinical practice Guidelines for the management of non-alcoholic fatty liver disease,” Journal of Hepatology, vol. 64, no. 6, pp. 1388–1402, 2016. View at: Google Scholar
52. American Diabetes Association, “Improving care and promoting health in populations: standards of medical care in Diabetes 2019,” Diabetes Care, vol. 42, no. 1, pp. S7–S12, 2019. View at: Publisher Site | Google Scholar
53. N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association,” Hepatology, vol. 55, no. 6, pp. 2005–2023, 2012. View at: Publisher Site | Google Scholar

Copyright

Copyright © 2020 Cristina M. Muzica et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.